[go: up one dir, main page]

Weber et al., 1982 - Google Patents

Multi-enzyme-targeted chemotherapy by acivicin and actinomycin

Weber et al., 1982

View PDF
Document ID
1508842693548843911
Author
Weber G
Prajda N
Lui M
Denton J
Aoki T
Sebolt J
Zhen Y
Burt M
Faderan M
Reardon M
Publication year
Publication venue
Advances in Enzyme Regulation

External Links

Snippet

On the basis of our observation of the increased specific activities of glutamine-utilizing enzymes in purine and pyrimidine metabolism in hepatoma 3924A, and because the concentration of glutamine is ten times lower in the hepatomas than in the liver, the …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1229—Phosphotransferases with a phosphate group as acceptor (2.7.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)

Similar Documents

Publication Publication Date Title
Weber et al. Multi-enzyme-targeted chemotherapy by acivicin and actinomycin
Momparler et al. Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia
Karakashian et al. The inhibition of a biological clock by actinomycin D
Pegg et al. S-adenosylmenthionine decarboxylase as an enzyme target for therapy
Kinahan et al. Biochemical and antitumor effects of the combination of thymidine and 1-β-D-arabinofuranosylcytosine against leukemia L1210
Peters et al. Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390)
Klubes et al. Effects of 5-fluorouracil on 5-fluorodeoxyuridine 5′-monophosphate and 2-deoxyuridine 5′-monophosphate pools, and DNA synthesis in solid mouse L1210 and rat Walker 256 tumors
Weber et al. Salvage capacity of hepatoma 3924A and action of dipyridamole
Müller et al. Effect of 9-β-D-arabinofuranosyladenine on DNA synthesis in vivo
Snider et al. The occurrence and functional significance of dopamine in some peripheral adrenergic nerves of the rat
Weber et al. Control of enzymic programs and nucleotide pattern in cancer cells by acivicin and tiazofurin
DiSorbo et al. In vivo and in vitro inhibition of B16 melanoma growth by vitamin B6
Kern et al. Glutamyl transfer ribonucleic acid synthetase of Escherichia coli. Study of the interactions with its substrates
Liu et al. Increased cytotoxicity and decreased in vivo toxicity of FdUMP [10] relative to 5-FU
Streifel et al. Synergistic interaction between 1-beta-D-arabinofuranosylcytosine, thymidine, and hydroxyurea against human B cells and leukemic blasts in vitro.
Tihan et al. Studies on the mechanisms of inhibition of L1210 cell growth by 3, 4-dihydroxybenzohydroxamic acid and 3, 4-dihydroxybenzamidoxime
Denton et al. Rapid in vivo inactivation by acivicin of CTP synthetase, carbamoyl-phosphate synthetase II, and amidophosphoribosyltransferase in hepatoma
Keppler Uridine triphosphate deficiency, growth inhibition, and death in ascites hepatoma cells induced by a combination of pyrimidine biosynthesis inhibition with uridylate trapping
Barron et al. THE EFFECT OF NITROGEN MUSTARDS ON ENZYMES AND TISSUE METABOLISM: II. The Effect on Tissue Metabolism
Pegg et al. Inhibition of bacterial aminopropyltransferases by S‐adenosyl‐1, 8‐diamino‐3‐thiooctane and by dicyclohexylamine
Chuang et al. Inhibition of RNA polymerase as a possible anti-leukaemic action of cytosine arabinoside
Kensler et al. Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma
Sufrin et al. Differential kinetic properties of L-2-amino-4-methylthio-cis-but-3-enoic acid, a methionine analog inhibitor of S-adenosylmethionine synthetase
Kerr et al. Regulation of the tRNA methyltransferases in normal and neoplastic tissues
Farnham Effect of aminonucleoside (of puromycin) on normal and encephalomyocarditis (EMC) virus-infected L cells